Shea W K, Cowens J W, Ip M M
Grace Cancer Drug Center, Roswell Park Cancer Institute, New York State Department of Health, Buffalo 14263.
J Steroid Biochem Mol Biol. 1991 Oct;39(4A):433-47. doi: 10.1016/0960-0760(91)90236-x.
Using a 17-mer synthetic peptide for immunization, a polyclonal antibody (WS933) directed against amino acid residues 395-411 of the mouse glucocorticoid receptor (GCR) has been raised and used to probe the significance of this region in forming the receptor oligomer and to localize the truncation site of the mutant GCR of the P1798 lymphosarcoma. This region of the receptor, which encompasses the BUGR epitope, is amino-terminal of and immediately adjacent to the DNA-binding domain. The polyclonal antibody WS933 reacted with both native and denatured forms of the wild-type mouse GCR as judged by its ability to shift the transformed receptor peak on Sephacryl S300 columns, to immunoadsorb the receptor to protein A Sepharose, and by immunoblot analysis where it identified the 98 kDa receptor protein in the cortisol-sensitive line of the P1798 mouse lymphosarcoma. WS933 also reacted with rat and rabbit GCR, but not human GCR. These characteristics were shared by the BUGR-2 monoclonal antibody. Unexpectedly, there were two highly significant differences between WS933 and BUGR-2. The first was the ability of WS933 to bind to the mutant 45 kDa GCR of the cortisol-resistant P1798 lymphosarcoma as judged by its capability of shifting the receptor peak on Sephacryl S300 columns. BUGR-2, in contrast, was unable to shift this mutant receptor peak. Secondly, WS933 was unable to react with the non-DNA-binding form of the wild-type (or mutant) GCR, whereas BUGR-2 could react with the non-DNA-binding form of the wild-type GCR. The first observation suggests that the truncation site of the mutant receptor may lie within a portion of the BUGR domain. Additionally, the second observation implies that at least part of the region lying within amino acid residues 395-411 of the mouse GCR is occluded in the receptor oligomer and that this site only becomes available upon transformation of the GCR to the DNA-binding form. This data provides the first mapping of the amino-terminus of the occluded region of the non-transformed receptor, and suggests that WS933 will be a useful probe for characterizing mutant as well as wild type glucocorticoid receptors.
利用一段17聚体合成肽进行免疫,制备了一种针对小鼠糖皮质激素受体(GCR)氨基酸残基395 - 411的多克隆抗体(WS933),并用于探究该区域在形成受体寡聚体中的意义,以及定位P1798淋巴肉瘤突变GCR的截短位点。受体的这一区域包含BUGR表位,位于DNA结合域的氨基末端且与之紧邻。通过其在Sephacryl S300柱上使转化受体峰发生位移的能力、将受体免疫吸附到蛋白A琼脂糖上的能力以及免疫印迹分析(在该分析中它能识别P1798小鼠淋巴肉瘤皮质醇敏感系中的98 kDa受体蛋白)判断,多克隆抗体WS933能与野生型小鼠GCR的天然形式和变性形式发生反应。WS933也能与大鼠和兔的GCR发生反应,但不能与人的GCR反应。BUGR - 2单克隆抗体也具有这些特性。出乎意料的是,WS933和BUGR - 2之间存在两个非常显著的差异。第一个差异是,通过其在Sephacryl S300柱上使受体峰发生位移的能力判断,WS933能够结合皮质醇抵抗性P1798淋巴肉瘤的45 kDa突变GCR。相比之下,BUGR - 2无法使该突变受体峰发生位移。其次,WS933不能与野生型(或突变型)GCR的非DNA结合形式发生反应,而BUGR - 2能够与野生型GCR的非DNA结合形式发生反应。第一个观察结果表明,突变受体的截短位点可能位于BUGR结构域的一部分内。此外,第二个观察结果意味着,小鼠GCR氨基酸残基395 - 411内的至少部分区域在受体寡聚体中被封闭,并且该位点仅在GCR转化为DNA结合形式时才会暴露。这些数据首次绘制了未转化受体封闭区域的氨基末端图谱,并表明WS933将是表征突变型以及野生型糖皮质激素受体的有用探针。